Eupraxia Pharmaceuticals Files 6-K, Submits Form 40-F

Ticker: EPRX · Form: 6-K · Filed: Sep 22, 2025 · CIK: 1581178

Sentiment: neutral

Topics: reporting, annual-report, foreign-private-issuer

TL;DR

Eupraxia Pharma (EPRX) filed a 6-K, submitting its 40-F annual report. Standard procedure.

AI Summary

Eupraxia Pharmaceuticals Inc. filed a Form 6-K on September 22, 2025, indicating it is submitting its annual report under cover of Form 40-F. The company, based in Victoria, British Columbia, Canada, operates in the Pharmaceutical Preparations sector.

Why It Matters

This filing signals Eupraxia Pharmaceuticals Inc. is meeting its annual reporting obligations as a foreign private issuer, which is crucial for maintaining its listing and providing transparency to investors.

Risk Assessment

Risk Level: low — This is a routine administrative filing for an annual report, not indicating new material events or financial distress.

Key Players & Entities

FAQ

What is the purpose of this Form 6-K filing?

The purpose of this Form 6-K filing is to report information required by Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, specifically to submit the registrant's annual report under cover of Form 40-F.

When was this Form 6-K filed?

This Form 6-K was filed on September 22, 2025.

What is Eupraxia Pharmaceuticals Inc.'s principal executive office address?

Eupraxia Pharmaceuticals Inc.'s principal executive office is located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4.

Does Eupraxia Pharmaceuticals Inc. file its annual reports under Form 20-F or Form 40-F?

Eupraxia Pharmaceuticals Inc. files its annual reports under cover of Form 40-F.

What is Eupraxia Pharmaceuticals Inc.'s SIC code?

Eupraxia Pharmaceuticals Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 172 words · 1 min read · ~1 pages · Grade level 13.1 · Accepted 2025-09-22 16:43:31

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. EUPRAXIA PHARMACEUTICALS INC. Date: September 22, 2025 By: /s/ Alex Rothwell Name: Alex Rothwell Title: Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing